XML 31 R24.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Segment Information | 6 Months Ended
--- | ---
Jun. 30, 2024
Segment Reporting [Abstract] |
Segment Information |
16. | Segment Information
The Company is a consolidated entity comprised of two distinct operating segments: Gyre Pharmaceuticals and Gyre after the Contributions. The Company’s reportable segments are based upon internal organizational structure, the manner in which operations are managed, the criteria used by CODM to evaluate segment performance, the availability of separate financial information, and overall materiality considerations. All Gyre’s operations are within the U.S., while all of Gyre Pharmaceuticals’ operations are in mainland China. Gyre Pharmaceuticals Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre Pharmaceuticals’ product revenues are mainly generated from the sale of ETUARY and certain generic drugs. Gyre Pharmaceuticals primarily sells its pharmaceutical products to distributors in the PRC, who ultimately sell the products to hospitals, other medical institutions and pharmacies. Gyre Pharmaceuticals also generates revenue from license agreements. However, the license agreements did not generate any revenue for the three and six months ended June 30, 2024 or 2023. Gyre Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States. Other than the IP associated with F351 in the U.S., Gyre has no other product candidates since the Company sold all of its legacy IP assets prior to the closing of the Contributions. Subsequent to the closing of the Contributions, Gyre has not generated any revenue. Other Other represents the financial information from other subsidiaries, consisting of mainly CPI, GNI HK, and Continent Pharmaceuticals U.S., Inc. During the year ended December 31, 2023, prior to the Contributions, CPI divested almost all of its assets other than its 56.0% indirect ownership interest in Gyre Pharmaceuticals (see Note 8 – Restructuring in the Annual Report). Segment information for the three and six months ended June 30, 2024 and 2023 is as follows (in thousands):
|  | Three Months Ended June 30, 2024 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Revenues |  | $ | 25,225 |  |  | $ | — |  |  | $ | — |  |  | $ | 25,225 |
Cost of revenues |  |  | 770 |  |  |  | — |  |  |  | — |  |  |  | 770 |
Gross profit |  |  | 24,455 |  |  |  | — |  |  |  | — |  |  |  | 24,455 |
Operating expenses excluding cost of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 14,414 |  |  |  | — |  |  |  | — |  |  |  | 14,414 |
Research and development |  |  | 3,077 |  |  |  | 278 |  |  |  | — |  |  |  | 3,355 |
General and administrative |  |  | 2,549 |  |  |  | 874 |  |  |  | 1 |  |  |  | 3,424 |
Total operating expenses excluding cost of revenues |  |  | 20,040 |  |  |  | 1,152 |  |  |  | 1 |  |  |  | 21,193 |
Income (loss) from operations |  | $ | 4,415 |  |  | $ | (1,152 | ) |  | $ | (1 | ) |  | $ | 3,262 |
Supplemental disclosure of stock-based compensation expense: |  |  |  |  |  |  |  |  |  |  |  |
General and administrative |  | $ | — |  |  | $ | 16 |  |  | $ | — |  |  | $ | 16 |
Stock-based compensation total |  | $ | — |  |  | $ | 16 |  |  | $ | — |  |  | $ | 16 |
|  | Six Months Ended June 30, 2024 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Revenues |  | $ | 52,397 |  |  | $ | — |  |  | $ | — |  |  | $ | 52,397 |
Cost of revenues |  |  | 1,749 |  |  |  | — |  |  |  | — |  |  |  | 1,749 |
Gross profit |  |  | 50,648 |  |  |  | — |  |  |  | — |  |  |  | 50,648 |
Operating expenses excluding cost of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 26,956 |  |  |  | — |  |  |  | — |  |  |  | 26,956 |
Research and development |  |  | 5,086 |  |  |  | 451 |  |  |  | — |  |  |  | 5,537 |
General and administrative |  |  | 4,806 |  |  |  | 2,015 |  |  |  | 1 |  |  |  | 6,822 |
Total operating expenses excluding cost of revenues |  |  | 36,848 |  |  |  | 2,466 |  |  |  | 1 |  |  |  | 39,315 |
Income (loss) from operations |  | $ | 13,800 |  |  | $ | (2,466 | ) |  | $ | (1 | ) |  | $ | 11,333 |
Supplemental disclosure of stock-based compensation expense: |  |  |  |  |  |  |  |  |  |  |  |
General and administrative |  | $ | — |  |  | $ | 27 |  |  | $ | — |  |  | $ | 27 |
Stock-based compensation total |  | $ | — |  |  | $ | 27 |  |  | $ | — |  |  | $ | 27 |
|  | Three Months Ended June 30, 2023 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Revenues |  | $ | 29,329 |  |  | $ | — |  |  | $ | — |  |  | $ | 29,329 |
Cost of revenues |  |  | 1,077 |  |  |  | — |  |  |  | — |  |  |  | 1,077 |
Gross profit |  |  | 28,252 |  |  |  | — |  |  |  | — |  |  |  | 28,252 |
Operating expenses excluding cost of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 17,999 |  |  |  | — |  |  |  | — |  |  |  | 17,999 |
Research and development |  |  | 3,568 |  |  |  | — |  |  |  | — |  |  |  | 3,568 |
General and administrative |  |  | 1,174 |  |  |  | — |  |  |  | 537 |  |  |  | 1,711 |
Total operating expenses excluding cost of revenues |  |  | 22,741 |  |  |  | — |  |  |  | 537 |  |  |  | 23,278 |
Income (loss) from operations |  | $ | 5,511 |  |  | $ | — |  |  | $ | (537 | ) |  | $ | 4,974 |
Supplemental disclosure of stock-based compensation expense: |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation total |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
|  | Six Months Ended June 30, 2023 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Revenues |  | $ | 54,260 |  |  | $ | — |  |  | $ | — |  |  | $ | 54,260 |
Cost of revenues |  |  | 2,202 |  |  |  | — |  |  |  | — |  |  |  | 2,202 |
Gross profit |  |  | 52,058 |  |  |  | — |  |  |  | — |  |  |  | 52,058 |
Operating expenses excluding cost of revenues: |  |  |  |  |  |  |  |  |  |  |  |
Selling and marketing |  |  | 30,767 |  |  |  | — |  |  |  | — |  |  |  | 30,767 |
Research and development |  |  | 6,203 |  |  |  | — |  |  |  | — |  |  |  | 6,203 |
General and administrative |  |  | 2,896 |  |  |  | — |  |  |  | 554 |  |  |  | 3,450 |
Total operating expenses excluding cost of revenues |  |  | 39,866 |  |  |  | — |  |  |  | 554 |  |  |  | 40,420 |
Income (loss) from operations |  | $ | 12,192 |  |  | $ | — |  |  | $ | (554 | ) |  | $ | 11,638 |
Supplemental disclosure of stock-based compensation expense: |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation total |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
The table below presents total assets as of June 30, 2024 and December 31, 2023.
|  | June 30, 2024 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Total assets |  | $ | 109,484 |  |  | $ | 10,533 |  |  | $ | 912 |  |  | $ | 120,929 |
|  | December 31, 2023 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Total assets |  | $ | 101,761 |  |  | $ | 13,865 |  |  | $ | 913 |  |  | $ | 116,539 |
The table below only includes cash outflows for the purchase of property and equipment and excludes non-cash activities.
|  | Six Months Ended June 30, 2024 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Purchase of property and equipment |  | $ | 1,673 |  |  | $ | 14 |  |  | $ | — |  |  | $ | 1,687 |
|  | Six Months Ended June 30, 2023 |
|  | Gyre Pharmaceuticals |  |  | Gyre |  |  | Other |  |  | Consolidated |
Purchase of property and equipment |  | $ | 4,219 |  |  | $ | — |  |  | $ | — |  |  | $ | 4,219 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration